miR-155 has been shown to be a potent pro-inflammatory mediator found at increased levels in the mucosa of IBD patients, suppressing SOCS1 and negative inhibitors of TLR4, thereby increasing IL-6 and IL-8 from immune cells including intestinal myofibroblasts (40, 41). Here, TLR4 is linked to inflammatory bowel disease.